A New Aura Of Relief: The Future of Migraine Treatment

306
0
pexels liza summer 6382648 1

The World Health Organisation rates migraine as the most common, debilitating, long-term neurological condition1. Globally, migraines affect more than 10% of people, primarily those between the ages of 20 and 50. Migraines are also three times more common in women than men. About one-third of migraineurs are able to anticipate when an episode is about to begin as it is preceded by an ‘aura’ or visual abnormalities like flashing lights, zigzag lines, or a temporary loss of vision2.

A severe pulsing or throbbing pain in one area of the head is a common way to describe the discomfort of a migraine headache. The International Headache Society defines a migraine as pain with at least five attacks, lasting four to 72 hours if left untreated, as well as other symptoms including nausea, vomiting, or sensitivity to light and sound3. Depending on the number of days a month a person has headaches, a migraine can be classified as either episodic (EM) or chronic (CM). When a migraine sufferer has fewer than 15 headache days per month, they are said to have episodic migraine, according to the International Classification of Headache Disorders (ICHD-2) criteria. 15 or more . . .

This exclusive content is reserved for our valued members. Kindly log in or sign up to enjoy full access and delve into the complete article.
Dr. Keertana
WRITTEN BY

Dr. Keertana

PharmD
A medical writer with a Doctorate in Pharmacy, she writes vividly about medicine and science. Read her contributions and writings about various healthcare topics.